These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 15579746

  • 21. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 22. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
    Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF.
    J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
    Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R.
    Am Heart J; 2002 Oct; 144(4):E6. PubMed ID: 12360175
    [Abstract] [Full Text] [Related]

  • 24. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 25. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
    Ishigami M, Yamashita S, Sakai N, Hirano K, Hiraoka H, Nakamura T, Matsuzawa Y.
    Atherosclerosis; 2003 Jun; 168(2):359-66. PubMed ID: 12801620
    [Abstract] [Full Text] [Related]

  • 26. Minor components of olive oil facilitate the triglyceride clearance from postprandial lipoproteins in a polarity-dependent manner in healthy men.
    Cabello-Moruno R, Martinez-Force E, Montero E, Perona JS.
    Nutr Res; 2014 Jan; 34(1):40-7. PubMed ID: 24418245
    [Abstract] [Full Text] [Related]

  • 27. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

  • 28. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 29. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity.
    Adiels M, Matikainen N, Westerbacka J, Söderlund S, Larsson T, Olofsson SO, Borén J, Taskinen MR.
    Atherosclerosis; 2012 May; 222(1):222-8. PubMed ID: 22365426
    [Abstract] [Full Text] [Related]

  • 30. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
    Nordøy A, Svensson B, Hansen JB.
    J Thromb Haemost; 2003 Apr; 1(4):690-7. PubMed ID: 12871402
    [Abstract] [Full Text] [Related]

  • 31. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [Abstract] [Full Text] [Related]

  • 32. Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis.
    Kushiya F, Wada H, Ooi K, Sakurai Y, Sakaguchi A, Noda M, Abe Y, Nakasaki T, Tsukada T, Shiku H, Nobori T.
    Am J Hematol; 2005 Jan; 78(1):1-6. PubMed ID: 15609278
    [Abstract] [Full Text] [Related]

  • 33. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis.
    van Wijk JP, Buirma R, van Tol A, Halkes CJ, De Jaegere PP, Plokker HW, van der Helm YJ, Castro Cabezas M.
    Atherosclerosis; 2005 Jan; 178(1):147-55. PubMed ID: 15585212
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
    Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen T, Thuren T, Shear CL, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):148-54. PubMed ID: 17951324
    [Abstract] [Full Text] [Related]

  • 35. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
    Kucera M, Oravec S, Hirnerova E, Huckova N, Celecova Z, Gaspar L, Banach M.
    Angiology; 2014 Oct; 65(9):794-9. PubMed ID: 24163116
    [Abstract] [Full Text] [Related]

  • 36. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
    Nordøy A, Hansen JB, Brox J, Svensson B.
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326
    [Abstract] [Full Text] [Related]

  • 37. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia.
    Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):811-6. PubMed ID: 12006395
    [Abstract] [Full Text] [Related]

  • 38. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 01; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 39. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
    Lee SH, Park S, Kang SM, Jang Y, Chung N, Choi D.
    J Cardiovasc Pharmacol Ther; 2012 Mar 01; 17(1):65-71. PubMed ID: 21386036
    [Abstract] [Full Text] [Related]

  • 40. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
    Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD.
    Arterioscler Thromb Vasc Biol; 2003 Jul 01; 23(7):1289-94. PubMed ID: 12750118
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.